Table of Contents

Targeting type 2 diabetes.
Dual acting and pan-PPAR activators as potential anti-diabetic therapies.
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
SGLT inhibitors as new therapeutic tools in the treatment of diabetes.
Inhibitors of 11[beta]-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Nampt and its potential role in inflammation and type 2 diabetes.
Inhibition of ganglioside biosynthesis as a novel therapeutic approach in insulin resistance.
Overcoming insulin resistance with ciliary neurotrophic factor.
Thermogenesis and related metabolic targets in anti-diabetic therapy.
Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes.
Fructose-1, 6-bisphosphatase inhibitors for reducing excessive endogenous glucose production in type 2 diabetes.
AMP-activated protein kinase and metabolic control.
Mitochondria as potential targets in antidiabetic therapy.
Research and development of glucokinase activators for diabetes therapy : theoretical and practical aspects.